Alpine Immune Sciences Inc. (ALPN)
64.97
0.01 (0.02%)
May 17, 2024, 8:00 PM - Market open
0.02% (1D)
| Bid | n/a |
| Market Cap | 4.46B |
| Revenue (ttm) | 56.52M |
| Net Income (ttm) | -36.84M |
| EPS (ttm) | -0.64 |
| PE Ratio (ttm) | -101.515625 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | n/a |
| Volume | 4,288,333 |
| Avg. Volume (20D) | 2,371,991 |
| Open | 64.98 |
| Previous Close | 64.96 |
| Day's Range | 64.97 - 65.00 |
| 52-Week Range | 8.33 - 65.00 |
| Beta | 0.97 |
About ALPN
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 17, 2015
Employees 142
Stock Exchange NASDAQ
Ticker Symbol ALPN
Analyst Forecast
According to 1 analyst ratings, the average rating for ALPN stock is "Hold." The 12-month stock price forecast is $65, which is an increase of 0.05% from the latest price.
Stock Forecasts